C12Y 301/08001
Aryldialkylphosphatase , i.e. paraoxonase
Official title: Aryldialkylphosphatase (3.1.8.1), i.e. paraoxonase
C12Y301/08001 (Aryldialkylphosphatase , i.e. paraoxonase) appears on 32 US grants and 56 published applications in this corpus.
Search patents in C12Y- Granted patents
- 32
- Published applications
- 56
- Assignees
- 40
- Inventors
- 98
- Latest grant
- 14 Jul 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2007 | 0 | 1 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 1 |
| 2012 | 0 | 5 |
| 2013 | 2 | 3 |
| 2014 | 2 | 2 |
| 2015 | 4 | 3 |
| 2016 | 1 | 5 |
| 2017 | 3 | 3 |
| 2018 | 1 | 1 |
| 2019 | 3 | 4 |
| 2020 | 1 | 5 |
| 2021 | 0 | 3 |
| 2022 | 2 | 2 |
| 2023 | 3 | 6 |
| 2024 | 3 | 5 |
| 2025 | 5 | 6 |
| 2026 | 2 | 1 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Pharmaceutical formulations, methods for treating chemical warfare agent exposure, and modified biomolecules14 Jul 2026US 12,680,090 B1Teledyne FLIR Defense, Inc.
- Stabilized mutants of quorum quenching lactonase and use thereof in treatment of pathogens30 Jun 2026US 12,667,106 B2Migal Galilee Research Institute Ltd.
- Polynucleotides encoding APOA-1 fusion polypeptides30 Dec 2025US 12,509,501 B2Theripion, Inc.
- RNase-PON1 fusion polypeptides and related compositions and methods16 Dec 2025US 12,497,604 B2Theripion, Inc.
- APOA-1 fusion polypeptides and related compositions17 Jun 2025US 12,331,102 B2Theripion, Inc.
- Methods for treating acute coronary syndrome using apoa-1 fusion proteins5 Mar 2026US 2026/0062460 A1Theripion, Inc.
- Recombinant plasmid vectors, method for producing enzymes that hydrolyze organophosphate, carbamate, and pyrethroid insecticides, and the formulation of such enzymes as functional components27 Nov 2025US 2025/0361495 A1Biom, LLC
- Random Heteropolymers Preserve Protein Function in Foreign Environments7 Aug 2025US 2025/0250607 A1The Regents of the University of California
- Polynucleotides encoding apoa-1 fusion polypeptides26 Jun 2025US 2025/0206806 A1Theripion, Inc.
- Rnase-pon1 fusion polypeptides and related compositions and methods15 May 2025US 2025/0154484 A1Theripion, Inc.
Most cited
By later US patents
- Paraoxonase fusion polypeptides and related compositions and methods5US 12,180,521 B2Theripion, Inc. · 2024
- Isolated PON1 polypeptides, polynucleotides encoding same and uses thereof in treating or preventing organophosphate exposure associated damage5US 8,735,124 B2Yeda Research and Development Co. Ltd. · 2014
- Sulfolobal phosphotriesterase-like (PLL) lactonases activity having enhanced properties and the uses thereof3US 10,072,252 B2Centre National De La Recherche Scientifique · 2018
- DFPase enzymes from Aplysia californica3US 8,709,773 B2Novozymes A/S · 2014
- Variants of phosphotriesterase for the hydrolysis and detoxification of nerve agents2US 10,301,608 B2The Texas A&M University System · 2019